ConductScience.org, home

Comparison · NCT02467621-b5357079

Proton Pump Inhibitor (PPI) vs Normal Saline: Number of Serious Adverse Reactions

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Proton Pump Inhibitor (PPI) vs Normal Saline: Number of Serious Adverse Reactions. Trial comparisons, record NCT02467621-b5357079. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02467621-b5357079

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 1000.00233wilson
Risk in group 2000.00233wilson
Risk difference, group 1 minus group 20-0.002330.00233newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to treatfrom the risk difference intervalthe two groups' risks are equal

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Proton Pump Inhibitor (PPI)Pantoprazole 40 mg~Pantoprazole: 40 mg x 1 daily intravenously from ICU admission to ICU discharge01,644OG000
Group 2Normal SalineSaline (0.9%)~Saline (0.9%): 10 ml of isotonic saline x 1 daily intravenously from ICU admission to ICU discharge01,647OG001

Outcome

Type
SECONDARY
Title
Number of Serious Adverse Reactions
Description
Serious adverse reactions are: anaphylactic reactions, agranulocytosis, pancytopenia, acute hepatic failure, Steven Johnsons Syndrome and toxic epidermal necrolysis, interstitial nephritis and angioedema.
Time frame
Until ICU discharge, maximum 90 days
Population

Source ClinicalTrials.gov

Trial

Title
Stress Ulcer Prophylaxis in the Intensive Care Unit
NCT number
NCT02467621
Phases
PHASE4
Conditions
Gastrointestinal Bleeding, Stress Ulcers
Interventions
Pantoprazole, Saline (0.9%)
Lead sponsor
Dr. Morten Hylander Møller
Results first posted
2019-06-07

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02467621-b5357079